Newly diagnosed depression is associated with increased beta-thromboglobulin levels and increased expression of platelet activation markers and platelet derived CD40-CD40L

Journal of Psychiatric Research

Volumn 47, Issue 7, 2013, Pages 865-871

  Neubauer, Horst ^a   Petrak, Frank ^b   Zahn, Daniela ^c   Pepinghege, Fenena ^a   Hägele, Anna Karolina ^b   Pirkl, Pia Alexandra ^b   Uhl, Idun ^b   Juckel, Georg ^b   Mügge, Andreas ^a   Herpertz, Stephan ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Beta thromboglobulin; CD40 CD40L; Depression; P selectin; Platelets

Indexed keywords

BETA THROMBOGLOBULIN; BIOLOGICAL MARKER; CD40 ANTIGEN; CD40 LIGAND; PADGEM PROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

EID: 84877119949     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.03.011     Document Type: Article

References (47)

1. Anand S.X., Viles-Gonzalez J.F., Badimon J.J., Cavusoglu E., Marmur J.D. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thrombosis Haemostasis 2003, 90:377-384.
2. Andrade C., Sandarsh S., Chethan K.B., Nagesh K.S. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. Journal of Clinical Psychiatry 2010, 71:1565-1575.
3. Antoniades C., Bakogiannis C., Tousoulis D., Antonopoulos A.S., Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. Journal of the American College of Cardiology 2009, 54:669-677.
4. Barefoot J.C., Brummett B.H., Helms M.J., Mark D.B., Siegler I.C., Williams R.B. Depressive symptoms and survival of patients with coronary artery disease. Psychosomatic Medicine 2000, 62:790-795.
5. Bruce E.C., Musselman D.L. Depression, alterations in platelet function, and ischemic heart disease. Psychosomatic Medicine 2005, 67(1):S34-S36.
6. Buckley D.I., Fu R., Freeman M., Rogers K., Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2009, 151:483-495.
7. Chamberlain A.M., Vickers K.S., Colligan R.C., Weston S.A., Rummans T.A., Roger V.L. Associations of preexisting depression and anxiety with hospitalization in patients with cardiovascular disease. Mayo Clinic Proceedings 2011, 86:1056-1062.
8. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. Journal of Clinical Investigation 2005, 115:3378-3384.
9. Glassman A.H., O'Connor C.M., Califf R.M., Swedberg K., Schwartz P., Bigger J.T., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. Journal of the American Medical Association 2002, 288:701-719. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group.
10. Henn V., Slupsky J.R., Gräfe M., Anagnostopoulos I., Förster R., Müller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
11. Henn V., Steinbach S., Buchner K., Presek P., Kroczek R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001, 98:1047-1054.
12. Hermann A., Rauch B.H., Braun M., Schror K., Weber A.A. Platelet CD40 ligand (CD40L): subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001, 12:74-82.
13. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 2009, 71:171-186.
14. Iijima R., Byrne R.A., Ndrepepa G., Braun S., Mehilli J., Berger P.B., et al. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart 2009, 95:107-112.
15. Kroenke K., Spitzer R.L. The PHQ-9: a new depression and diagnostic severity measure. Psychiatric Annals 2002, 32:509-521.
16. Laghrissi-Thode F., Wagner W.R., Pollock B.G., Johnson P.C., Finkel M.S. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biological Psychiatry 1997, 42:290-295.
17. Leo R., Di Lorenzo G., Tesauro M., Razzini C., Forleo G.B., Chiricolo G., et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. Journal of Clinical Psychiatry 2006, 67:1760-1766.
18. Lichtman J.H., Bigger J.T., Blumenthal J.A., Frasure-Smith N., Kaufmann P.G., Lespérance F., et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008, 118:1768-1775.
19. Lorente L., Martín M.M., Varo N., Borreguero-León J.M., Solé-Violán J., Blanquer J., et al. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Critical Care 2011, 15:97.
20. Lukasik M., Dworacki G., Kufel-Grabowska J., Watala C., Kozubski W. Upregulation of CD40 ligand and enhanced monocyte-platelet aggregate formation are associated with worse clinical outcome after ischaemic stroke. Thrombosis and Haemostasis 2012, 107:346-355.
21. Michelson A.D. Evaluation of platelet function by flow cytometry. Pathophysiology of Haemostasis and Thrombosis 2006, 35:67-82.
22. Musselman D.L., Marzec U., Davidoff M., Manatunga A.K., Gao F., Reemsnyder A., et al. Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment. Depression and Anxiety 2002, 15:91-101.
23. Neubauer H., Krüger J.C., Lask S., Endres H.G., Pepinghege F., Engelhardt A., et al. Comparing the antiplatelet effect of clopidogrel hydrogen sulfate and clopidogrel besylate: a crossover study. Clinical Research in Cardiology 2009, 98:533-540.
24. Neubauer H., Setiadi P., Günesdogan B., Pinto A., Börgel J., Mügge A. Influence of glycemic control on upregulated platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in type 2 diabetes. Diabetic Medicine 2010, 27:384-390.
25. Pamukcu B., Lip G.Y., Snezhitskiy V., Shantsila E. The CD40-CD40L system in cardiovascular disease. Annals of Medicine 2011, 43:331-340.
26. Pan A., Sun Q., Okereke O.I., Rexrode K.M., Hu F.B. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. Journal of the American Medical Association 2011, 306:1241-1249.
27. Parakh K., Sakhuja A., Bhat U., Ziegelstein R.C. Platelet function in patients with depression. Southern Medical Journal 2008, 101:612-617.
28. Poole L., Dickens C., Steptoe A. The puzzle of depression and acute coronary syndrome: reviewing the role of acute inflammation. Journal of Psychosomatic Research 2011, 71:61-68.
29. Pratt L.A., Ford D.E., Crum R.M., Armenian H.K., Gallo J.J., Eaton W.W. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996, 94:3123-3129.
30. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunology 2006, 27:24-31.
31. Ross R. Atherosclerosis-an inflammatory disease. New England Journal of Medicine 1999, 340:115-126.
32. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., Arnow B., Klein D.N., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 2003, 54:573-583.
33. Schins A., Hamulyák K., Scharpé S., Lousberg R., Van Melle J., Crijns H., et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences 2004, 76:637-650.
34. Serebruany V.L., Glassman A.H., Malinin A.I., Nemeroff C.B., Musselman D.L., van Zyl L.T., et al. Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003, 108:939-944.
35. Serebruany V.L., Glassman A.H., Malinin A.I., Sane D.C., Finkel M.S., Krishnan R.R., et al. Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagulation and Fibrinolysis 2003, 14:563-567.
36. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The structured clinical interview for DSM-III-r (SCID). I: history, rationale, and description. Archives of General Psychiatry 1992, 49:624-629.
37. Tabachnick B.G., Fidell L.S. Using multivariate statistics 2007, Pearson Education Inc., Boston. 5th. ed.
38. Thombs B.D. Prevalence of depression in survivors of acute myocardial infarction. Journal of General Internal Medicine 2006, 21:30-38.
39. von Känel R. Platelet hyperactivity in clinical depression and the beneficial effect of antidepressant drug treatment: how strong is the evidence?. Acta Psychiatrica Scandinavica 2004, 110:163-177.
40. Weyrich A.S., Lindemann S., Zimmerman G.A. The evolving role of platelets in inflammation. Journal of Thrombosis and Haemostasis 2004, 1:1897-1905.
41. Whooley M.A., Caska C.M., Hendrickson B.E., Rourke M.A., Ho J., Ali S. Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. Biological Psychiatry 2007, 62:314-320.
42. Ye S., Muntner P., Shimbo D., Judd S.E., Richman J., Davidson K.W., et al. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: a REGARDS (Reason for geographic and racial differences in stroke) study. Journal of the American College of Cardiology 2012 Dec 27, (e-pub).
43. Zahn D., Petrak F., Uhl I., Juckel G., Neubauer H., Hägele A.K., et al. New pathways of increased cardiovascular risk in depression: a pilot study on the association of high-sensitivity C-reactive protein with pro-atherosclerotic markers in patients with depression. Journal of Affective Disorders 2012 Sep 18, (e-pub).
44. Zellweger M.J., Osterwalder R.H., Langewitz W., Pfisterer M.E. Coronary artery disease and depression. European Heart Journal 2004, 25:3-9.
45. Zeugmann S., Quante A., Heuser I., Schwarzer R., Anghelescu I. Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. Journal of Clinical Psychiatry 2010, 71:1007-1016.
46. Ziegelstein R.C., Parakh K., Sakhuja A., Bhat U. Platelet function in patients with major depression. Internal Medicine Journal 2009, 39:38-43.
47. Zuidersma M., Thombs B.D., de Jonge P. Onset and recurrence of depression as predictors of cardiovascular prognosis in depressed acute coronary syndrome patients: a systematic review. Psychotherapy and Psychosomatics 2011, 80:227-237.